HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anticancer Agents Med Chem 2008;8(5):488-96.Widakowich C,Dinh P,de Azambuja E,et al.HER-2 positive breast cancer:what else beyond trastuzumab-based therapy?.Anticancer Agents Med Chem. 2008...
[4] Smith I, Procter M, Gelber RD, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial[J]. Lancet,2007,369(9555):29-36. [5] Perez EA, Romond...
Up to one fourth of women diagnosed with early breast cancer (EBC) have tumors that are human epidermal growth factor receptor 2 (HER-2) positive. This is ... Baselga,J. - 《Oncologist》 被引量: 517发表: 2006年 Survival in patients with brain metastases from breast cancer: the importanc...
CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone receptor (HR)-positive and HER2-positive breast cancer (BC). In this phase 2 study (NCT04293276), we aim to evaluate a dual-oral regimen of CDK4/6 inhibitor dalpiciclib combined with HER2 tyrosine kinase ...
摘要 HER-2阳性乳腺癌侵袭性强、复发率高,针对HER-2的单靶向治疗虽使患者生存期得以延长,但仍有患者发生复发转移。双靶向治疗因其作用机制不重叠,具有协同作用,使患者生存期得以进一步延长。本文以曲妥珠单抗靶向治疗为基础,对...展开更多 Human epidermal growth factor receptor(HER)-2-positive breast cancer is ...
(albumin binding type) combined with carboplatin and targeted drugs-trastuzumab has a significant curative effect in treatment of HER-2 positive breast cancer, which can improve the immune function of patients and up-regulate tumor suppressor genes, thereby improving survival rate and benefiting ...
In the TBCRC003 trial of lapatinib and trastuzumab, a genetic analysis of biopsies from metastatic tumors compared with primary treatment-naive HER2-positive breast cancer showed that the rate of HER2 mutations differed significantly between the two groups.[16] Some of those are known, activating ...
雄激素受体(AR)在HER-2过表达型乳腺癌中的作用及机制研究进展 雄激素受体（ＡＲ）在ＨＥＲ－２过表达型乳腺癌中的作用及机制研究进展吴 洋，宋燕妮 ＲｅｓｅａｒｃｈｐｒｏｇｒｅｓｓｏｆｔｈｅｒｏｌｅａｎｄｍｅｃｈａｎｉｓｍｏｆＡＲｉｎＨＥＲ－２ｏｖｅｒｅｘｐｒｅｓｓｉｎｇｂｒｅａｓｔｃａｎｃｅｒ ＷＵＹ...
47 and 4. 87 months in patients with positive TIP30 expression and negative TIP30 expression,respectively( all P 0. 01). Conclusion The down-regulated TIP30 expression in HER-2-positive advanced breast cancer may be associated with the poor prognosis,which could be an important biomarker in ...
: In HER-2 positive breast cancer patients, the expression of P95HER-2 was correlated with hormone receptor status, Ki-67 expression, nerve invasion and overall survival, however, larger studies are needed to confirm the association with different prognostic factors and their impact on survival. ...